Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate in Hemodialysis Patients
jRCT2080220593Phase 2
- Sponsor
- Novartis
- Start
- Aug 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of SBR759 in hyperphosphatemia and chronic kidney disease (CKD), sponsored by Novartis.
02
Drugs
SBR759
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080220593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220593.